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number of patients, course-length, and repeated courses. Similar to the
observation by Ionescu et al(2), the pre-training inter-observer ICC value
was very high(0.867), and it increased to 0.905 after the training. Pres-
ence of an increase in some areas, and reduction in some others in
individual analysis of areas after the training may suggests the need for
repeated training. Our limitations were low number of participants and
patients. We obtained very good inter-rater ICC values in the mRSS
training course given to rheumatology fellows; however we may benefit
from new studies for optimization of these conclusions by increasing the
numbers of trainees, patients, and the lenght of courses.
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Background: Skin ulcers (SU) represent one of the most frequent compli-
cations of Systemic Sclerosis (SSc), characterized by severe chronic pain
and frequent complications. Pain related to SSc SU(SSU) remains yet an
area of significant unmet need. Moreover, pain control is fundamental for
the wound care procedures in SSc patients (pt), increasing treatment
adherence and compliance to skin ulcers dressing changes. The pain
relief provided by standard therapy (i.e. NSAIDs, tramadol) is often inad-
equate or dose limited by side effects. Opioids currently are the mainstay
of SSU pain treatment but burdened by side effect profile and/or ineffec-
tive. Thus, novel analgesic strategies need to be investigated. Cannabidiol
(CBD), one of many constituents of the Cannabis sativa, has received
renewed interest in the treatment of numerous pathological conditions.
Objectives: Evaluate our experience to define the efficacy of CBD prepa-
ration in patients with SSU.
Methods: 25 SSc pt (F/M 22/3, mean age 52.3 ± 12.9-SD-years),
referred to our Scleroderma Unit during 2018, were consecutively
included. In all pt the disease was complicated by long-standing, painful
SU resistant to opioids. Pain was classified as severe, according to
WHO guidelines in all subjects. 25/25 pt carried out systemic (calcium-
channel blockers, prostanoids and/or anti-ET receptors) and local (debride-
ment and dressing) therapies. The CBD (10% oral administration oil) was
used daily for the treatment of SSU-related pain. We performed both an
oral (five drops bid) as local treatment (two drops in the site of SSU)
during surgical debridement of SSU for a period of 5.9 ± 3.2 SD
months. Patients have been provided with a diary to record the following
symptoms daily: self-evaluation of pain at the same time in the evening,
using a visual analog scale (VAS), use of other analgesics, eventual side
effects. Health Assessment Questionnaire-Disability Index (HAQ-DI) was
administrated baseline and at the end of treatment. Safety of CBD was
evaluated by patient’s records of side effects, while vital signs and labo-
ratory parameter variations were monitored at each weekly medication.
Results: The local treatment with CBD produced a significant reduction of
SSU-related pain. After 1 month of therapy, pain VAS decreased from
94.8 ± 8.72 SD to 54.7 ± 9.4 SD (P<0.0001), total hours of sleep
increased from 2.56 ±1.28 SD to 5.67 ± 0.85 SD (P <0.000). Additional
analgesic therapy was necessary in 12/25 (48%). After 2 months, further
clinical improvement was observed: the pain VAS reduced to 40.9 ± 12.9
SD, the mean total hours of sleep per night was 6.10 ± 0.85 SD and
the HAQ-DI decreased from 1.1 ± 0.67 SD (baseline) to 0.46 ± 0.46 SD
at the last patients’ evaluation, when complete healing of SSU and pain
relief were obtained and CBD was discontinued. 20/25 (80%) pt regis-
tered a better compliance to the local wound management.
No reported significant side effects with CBD oil.
Conclusion: Our study suggests that the use of CBD as a local therapy
is effective and safe in maintaining analgesia in patients with SSU; not
secondarily it could be essential for an adequate healing of a local wound
with consequent improvement of SSc patients’ quality of life and compliance
on local SSU management. Further larger-scale studies will be needed to
finally demonstrate CBD efficacy and to monitor long-term effects.
Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2019-eular.6004
AB0646 HEALTHCARE UTILIZATION AMONG INCIDENT CASES
OF SYSTEMIC SCLEROSIS: RESULTS FROM A
POPULATION-BASED COHORT (1988–2016)
1Caitrin Coffey*, Avneek Singh Sandhu1, Cynthia S. Crowson2, Dennis Asante3,
Eric Matteson2, Thomas G. Osborn2, Kenneth J. Warrington2, Ashima Makol2.
1Mayo Clinic, Rochester, MN, United States of America; 2Mayo Clinic,
Rheumatology, Rochester, MN, United States of America; 3Mayo Clinic, Health
Sciences Research, Rochester, MN, United States of America
Background: Systemic sclerosis (SSc) is an autoimmune disorder associ-
ated with multi-organ dysfunction including but not limited to vascular,
cardiac and pulmonary involvement. Few studies have estimated the
healthcare resource usage of patients with SSc.
Objectives: To compare healthcare utilization among incident cases of
SSc vs age- and sex-matched comparators.
Methods: This study utilized a retrospective, population-based cohort of
physician-diagnosed patients with SSc in a geographically well-defined area
from Jan 1, 1988 to Dec 31, 2016. A 2:1 cohort of age- and sex-
matched non-SSc subjects from the same population base was randomly
selected for comparison. Inpatient and outpatient utilization data were
obtained from the Rochester Epidemiology Project beginning 12 months
prior to the SSc incidence/index date. Patients were followed until death,
migration from Olmsted County, or December 31, 2017. A maximum of 5
years following the incidence/index date was used for analysis and the fol-
low-up of each matched triple was further truncated at the shortest length
of follow-up for any member, to ensure similar periods of observation for
SSc cases and non-SSc comparators. Services were summarized as visit-
days (number of days at least one service in the category was billed) to
avoid overestimation of services provided. Utilization was compared
between SSc and non-SSc cohorts using negative binomial models.
Results: The cohort included 69 incident SSc cases and 138 non-
SSc comparators (mean age of 57 ± 16 years at diagnosis/index, 90%
female for both cohorts; 87% [SSc] and 95% [non-SSc] Caucasian).
Patients with SSc had the highest utilization of outpatient physician, labo-
ratory and combined radiology visit-days during the year of the SSc diag-
nosis compared with the year prior to diagnosis or years 1-4 after
diagnosis of SSc (Table). Patients with SSc had higher utilization of out-
patient physician, laboratory and combined radiology visit-days annually
for the year prior to diagnosis of SSc and for each of the first 5 years
after diagnosis of Ssc compared to patients without SSc. Rate ratios
comparing utilization in patients with and without SSc ranged from 1.8 to
3.0 for all comparisons.
Conclusion: A higher utilization of outpatient physician, laboratory and
radiology visits was observed among patients with SSc compared to non-
SSc subjects throughout 5 years of disease duration, indicating high and
continued care needs in this patient population.


















-1-0 69/138 4 (1–9) 2 (0–6) 1.8 (1.2–2.7)
0-1 69/138 7 (4–12) 3 (0–5) 2.4 (1.7–3.3)
1-2 66/132 4 (2–11) 2 (0–4) 2.0 (1.4–2.9)
2-3 54/108 4 (2–10) 3 (0-5) 1.9 (1.4–2.7)
3-4 48/96 4 (2–10) 3 (1–5) 1.9 (1.3–2.6)
4-5 43/86 5 (2–12) 3 (0–6) 2.1 (1.4–3.0)
Labs -1-0 69/138 3 (0-8) 1 (0-3) 2.1 (1.4–3.3)
0-1 69/138 4 (2-10) 2 (0–3) 3.0 (2.0–4.6)
1-2 66/132 5 (1-8) 1 (0–3) 2.0 (1.3–3.2)
2-3 54/108 3 (1-9) 1 (0–4) 2.6 (1.7–4.3)
3-4 48/96 3 (1-10) 1 (0–3) 2.7 (1.7–4.1)
4-5 43/86 3 (1-12) 1 (0–3) 2.9 (1.7–4.7)
Radiology -1-0 69/138 2 (0–5) 0 (0–2) 2.1 (1.6–4.2)
0-1 69/138 3 (1–6) 1 (0–3) 2.6 (1.8–3.9)
1-2 66/132 2 (1–6) 0 (0–2) 1.9 (1.8–3.1)
2-3 54/108 2 (1–4) 1 (0–2) 2.1 (1.3–3.1)
3-4 48/96 2 (1–4) 1 (0–2) 2.0 (1.3–3.1)
4-5 43/86 2 (1–7) 1 (0–2) 2.6 (1.6–4.2)
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